Status:
UNKNOWN
Azacitidine and Homoharringtonine in JMML
Lead Sponsor:
Air Force Military Medical University, China
Collaborating Sponsors:
Qilu Hospital of Shandong University
Taian City Central Hospital
Conditions:
JMML
Eligibility:
All Genders
1-18 years
Phase:
NA
Brief Summary
Juvenile myelomonocytic leukemia (JMML) has a poor prognosis in general, with hematopoietic stem cell transplant (HSCT) remaining the standard of care for cure. Azacitidine and homoharringtonine, whic...
Eligibility Criteria
Inclusion
- Newly diagnosed JMML, with PB and BM confirming diagnosis prior to informed consent signature, with one of the following:
- somatic mutation in PTPN11
- somatic mutation in KRAS
- somatic mutation in NRAS and HbF % \> 5x normal value for age
- clinical diagnosis of neurofibromatosis Type 1.
Exclusion
- 1\. Any condition that would prevent the subject from participating in the study.
- 2\. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if participated in the study.
- 3\. Any condition that confounds the ability to interpret data from the study.
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04505995
Start Date
January 1 2020
End Date
January 1 2025
Last Update
August 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin, Tianjin Municipality, China, 300020